Underlying predisposition
As in many other fungal infections, those of the CNS are often seen as a complication of disease or treatment causing immunosuppression and other forms of host impairment. Even in cases where the so-called 'pathogenic' fungi occur in apparently healthy people, there must be some predisposition which selects these patients for dissemination from the mass of those exposed or locally infected (Deresinski, Galgiani and Stevens, 1977a (Symmers, 1968) and there is often a very large amount of fungus present (Fig. 1) (Speller et al., 1977) . (Speller et al., 1977 (Bindschadler and Bennett, 1969) ; and miconazole i.v. has given CSF concentrations of < 0.1-0-77 mg/l (Deresinski et al., 1977b) . Fisher et al. (1978) (Diamond and Bennett, 1973) . Details of the intrathecal route for amphotericin are given by Williams (1970) . Micon 
General problems
The general supportive care for any patient undergoing a long, debilitating illness, often with disturbance of consciousness, must not be forgotten.
Treatment of individual conditions

Coccidioidal meningitis
This is one of the most difficult CNS infections to treat, despite the resistance of most of the human population to dissemination of this disease, and the generally superficial situation of the lesions. Amphotericin has been the mainstay of treatment, with full intravenous regimens and a total dose in the region of 3-4 g. Intrathecal amphotericin should be instituted routinely and continued until the CSF returns towards normal and there is no serological evidence of active disease (Winn, 1962 (Deresinski et al., 1977a, b; Sung et al., 1977) .
Ambruticin, an antibiotic derived from a myxobacterium, is at present showing promise in animal experiments, with fungicidal effectiveness and good tolerance (Levine, Ringel and Cobb, 1978) , but no human use has yet been reported, and there are considerable differences between the acute murine infection and human coccidioidomycosis.
Cryptococcal meningitis
The classical treatment for cryptococcal meningitis is amphotericin B, and this is frequently effective by the intravenous route, in total doses in the region of 2.5-3.0 g. (Medoff, Comfort and Kobayashi, 1971; Block and Bennett, 1973) ; on the other hand, toxic effects may be increased (Medoff and Kobayashi, 1975 ). An extended series reported the safety and efficacy of the combination (Utz et al., 1975) Candidal infection This is becoming the commonest cerebral mycosis to be found at post-mortem, as disseminated lesions in the brain substance (Parker, McCloskey and Lee, 1978) , but less commonly presents as a meningoencephalitis that can be diagnosed and treated. Most reported cases have been treated with amphotericin, in shorter courses than those used for cryptococcosis and coccidioidomycosis, and with variable results; flucytosine has also been successful in almost all reported cases in which it has been tried.
Conclusion
All the major antifungal agents for systemic disease have a role in the treatment of CNS infection. The chronic, fluctuating and relapsing course of these infections, and the small number of patients treated at any medical centre, make assessment of the various agents extremely difficult (Krick and Remington, 1975) but amphotericin B is an established treatment, flucytosine has achieved a definite limited role, and miconazole is a most promising addition to therapeutics.
